The nation of Zimbabwe has rejected a major American healthcare agreement worth $367m (£272m) spanning five years because of the United States' insistence on confidential biological samples.
This move became public after a internal memorandum from December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the deal was "lopsided".
An official spokesman has since explained that the United States was seeking genetic material for research and commercial gain while refused to guarantee the resulting advantages from future vaccines.
"We will now turn to the challenging and unfortunate task of ending our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had donated more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged continued negotiations to reach a deal acceptable to both sides so the country's vital HIV treatment initiative can continue.
Broader Context
This development follows a similar situation in Kenya, where a high court halted a related health funding agreement following legal challenges were filed about the security of Kenyans' health data.
After returning to office last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump argued its expenditure was "wasteful" and his administration was pursuing government-to-government agreements to boost transparency and accountability.
According to statements, Sixteen African countries have to date agreed to these new health pacts, representing over $18.3bn in committed funds.
Specifics of the Declined Agreement
The money for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership could have provided immense benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving HIV treatment through US-supported initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"The proposal required Zimbabwe to provide its biological resources and data for a long time, with no corresponding guarantee of benefiting from any medical innovations – like new medicines or tests – that could be developed from that provided information," his statement read.
"In essence, our nation would provide the raw materials for medical research without any certainty that the resulting innovations would be available to our people if a future pandemic emerge."
National Interest and International Frameworks
He also pointed out that the American exit from the global health body and its pursuit of one-on-one deals were disrupting structures previously established via the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing system created to manage potential pandemics.
"This mechanism is designed to ensure that when a nation contributes its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We welcome continued discussions with our American counterparts on how future co-operation might be designed in a way that honours the sovereignty and interests of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the official position, but urged that negotiations must proceed given that much of the country's Aids initiatives relied on external financing.
"In cases where specific concerns exist, such as those involving information security or implementation frameworks, these can often be addressed via detailed discussion and mutually agreed protections," it added.
The halted deal underscores the continuing debate between accepting vital international aid and protecting a country's data in an ever more interconnected world.